Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study
Crossref DOI link: https://doi.org/10.1007/s13300-017-0284-1
Published Online: 2017-06-16
Published Print: 2017-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bu, Shi
,
Zhang, Xuelian
Zhu, Haiqing
Shuai, Ying
Xing, Xiaoyan
Yang, Wenying
Funding for this research was provided by:
Sanofi
Text and Data Mining valid from 2017-06-16
Article History
Received: 5 April 2017
First Online: 16 June 2017